Palbociclib and Exemestane are Active in Pretreated Low-Grade Serous Ovarian Cancer
Q: Is the topic relevant to the journal area of interest? Is it contemporary and interesting for
Comments: In the title, “Palbociclib and Exemestane is” must be replaced with “Palbociclib and Exemestane are”.
Abstract & Keywords
Q: Are all required components included in the abstract? Are the keywords appropriately chosen?
Q: Is the goal explicitly stated in the Introduction? Is its formulation clear and unambiguous?
Q: Is the paper's structure coherent? Is it in coherence with the goal of the paper?
Tools and Methods
Q: Are methods the author uses adequate and well used?
Discussion & Conclusion
Q: Is it related to the results presented before? Do you consider them as coherent?
Comments: The Discussion describes the possible therapy for reducing the prognosis of the disease providing relevant literature. This further states that the cell cycle inhibitors, combined with endocrine therapy, are attractive candidates for the treatment of low-grade ovarian cancers in the advanced disease stages. This also highlights that in the early stages of the disease, c-MYC might not be mutated, leading to the characteristic slow progression of low-grade ovarian cancers. Lastly, this report calls for further research in this field.
Q: Does the author utilize relevant literature?
Q: What is the level of the author’s knowledge? Does the author utilize all recent contributions relevant to the topic?
Q: Is the length of the paper adequate to the significance of the topic? Do you suggest shortening the paper without losing its value?
Figures & Tables
Q: Does the author use them suitably? Are legend and notations clear?
Q: Is it clear and understandable?
Comments: There are few issues found in the manuscript which are as follows:
· In Case Report, 9th sentence, “CA-125 first increased (2440 kU/l) but dropped eventually with resulting in biochemical” must be replaced with “CA-125 first increased (2440 kU/l) but dropped eventually resulting in biochemical”. In 12th sentence, “the patient then seeked advice in our hospital” must be written as “the patient then sought advice in our hospital”.
· In 24th sentence of Case Report, “of our best knowledge” must be “to our best knowledge,”. And in 25th sentence, “overview low-grade Ovarian Cancer Ovarian Cancer is known as the 4th most lethal cancer type in women” must be “low-grade ovarian cancer is known as the 4th most lethal cancer type in women”.
· In Discussion, 1st sentence, “we observed a prolonged tumor-control with decreasing tumor-marker and without the need of a further therapy after conducted surgery in the beginning of the disease” must be written as “we observed a prolonged tumor-control with decreasing tumor-marker and without the need for further therapy after conducted surgery in the beginning of the disease”.
Further comments on the paper
Comments: This case presents a 55-year-old woman with heavily pretreated rare metastatic micropapillary low grade serous ovarian cancer. Later, KRAS-mutation and c-MYC-amplification was detected. This further highlights a combination therapy with Palbociclib and Exemestane that results in a lasting response, opening a new opportunity for treatment in heavily pretreated metastatic micropapillary low-grade serous ovarian cancer.
Q: Would you recommend this manuscript for further publication?
A: Yes - Suitable to be published
If you have any questions and clarifications you can write to the journal.
Science Repository Team
This email is restricted to the intended user.
|Science Repository - Support|
Corresponding AuthorBeat Thürlimann
Kantonsspital St. Gallen, St. Gallen, Switzerland
Article TypeCase Report
Publication historyReceived: Tue 08, Dec 2020
Accepted: Tue 22, Dec 2020
Published: Thu 31, Dec 2020
Copyright© 2023 Beat Thürlimann. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Hosting by Science Repository.